Latest Breaking News On - Pharmaceutical preparations - Page 10 : comparemela.com
Objectionableness How To Know If A Microorganism Poses A Risk In Your Drug Product
pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
BioMed X Institute Today Announces Two New Research Groups in Autoimmunity and Drug Delivery in Coll
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Scandia Inc Announces Acquisition of Xtreme Organics Inc To Expand Growth In Medicinal Chemicals And Botanical Products Space
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Scandia Inc Announces Plans to Reduce Its Authorized Shares From 20 Billion To 500 Million
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Search jobs VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development
HEIDELBERG, Germany and ZUG, Switzerland, June 14, 2021 / B3C newswire / VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), a leading company in innovative ADC engineering and functional antibody screening, announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the treatment of oncological conditions. The collaboration will leverage both the advantages of VERAXA s advanced and proprietary position-true click-chemistry-based drug conjugation technology in combination with Quadira’s superior 3D cellular assay and assessment systems. The agreement provides that VERAXA will be entitled to upfront payments and royalties from the worldwide sale of products resulting from the collaboration. Further details of the agreement were not disclosed.